Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection

Danis N., TÖZ H., ÜNAL N. G., YILMAZ M., TURAN İ., Gunsar F., ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.30, sa.8, ss.695-701, 2019 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 8
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5152/tjg.2019.18833
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.695-701
  • Anahtar Kelimeler: Paritaprevir, ritonavir, ombitasvir, dasabuvir, renal transplant, hepatitis C, ANTIVIRAL THERAPY, RECIPIENTS, EFFICACY, IMPACT, SAFETY
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Background/Aims: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the present study was to investigate the efficacy and safety of PrOD in RT patients with hepatitis C virus (HCV) infection in a single center real-life experience.